UNSPSC 51451904: Salantel

This classification denotes an antihelminthic agent with the molecular formula C20H11Cl2I2NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BIY8B0682Q, chemically known as 3-chloro-4-(p-chlorobenzoyl)-3,5-diiodosalicylanilide but generally known as salantel, which bears US NIH Compound Identifier 185463. European Medicines Agency schedules Salantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10417MIG.

UNSPSC 51451904 Salantel, a Commodity code, covers the supply of naloxone and related opioid-response pharmaceuticals and systems that state and local health agencies are now actively procuring to support overdose-reversal programs and community health initiatives. The code encompasses both finished pharmaceutical products and specialized drug-deactivation or safe-handling systems, with the pharmaceutical component dominating recent solicitation activity. State and local buyers under this code include county health departments, city fire rescue divisions, and state health and human services agencies; Seminole County, Florida and the City of Tampa Fire Department are recent purchasers, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission represent regional and statewide procurement actors expanding pharmacy procurement frameworks.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa issued IFB 26P00145 (due March 13, 2026) for medical and first aid supplies to the Tampa Fire Department Rescue Division, estimated at $700,000.00, with a 5% bid discount for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (due March 26, 2026) to establish contracts for generic pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon. The Texas Health and Human Services Commission issued RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling state-level exploration of broader pharmacy procurement models. Contract terms typically run one to two years with renewal options; vendors must comply with drug-free workplace certification, E-Verify requirements, insurance minimums, FDA cGMP standards, and compliance with the Drug Supply Chain Security Act.